Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
Saved in:
| Title: | Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. |
|---|---|
| Authors: | He, Chaoneng1,2 (AUTHOR), Mi, Xiufang2 (AUTHOR), Xu, Gaoqi2 (AUTHOR), Xu, Xinglu2 (AUTHOR), Xin, Wenxiu2 (AUTHOR), Zhong, Like2 (AUTHOR), Zhu, Junfeng2 (AUTHOR), Shu, Qi2 (AUTHOR), Fang, Luo2 (AUTHOR) dinghy@zjcc.org.cn, Ding, Haiying2,3 (AUTHOR) dinghy@zjcc.org.cn |
| Source: | PLoS ONE. 5/15/2024, Vol. 19 Issue 5, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 177250069 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22He%2C+Chaoneng%22">He, Chaoneng</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mi%2C+Xiufang%22">Mi, Xiufang</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xu%2C+Gaoqi%22">Xu, Gaoqi</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xu%2C+Xinglu%22">Xu, Xinglu</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xin%2C+Wenxiu%22">Xin, Wenxiu</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhong%2C+Like%22">Zhong, Like</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhu%2C+Junfeng%22">Zhu, Junfeng</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shu%2C+Qi%22">Shu, Qi</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fang%2C+Luo%22">Fang, Luo</searchLink><relatesTo>2</relatesTo> (AUTHOR)<i> dinghy@zjcc.org.cn</i><br /><searchLink fieldCode="AR" term="%22Ding%2C+Haiying%22">Ding, Haiying</searchLink><relatesTo>2,3</relatesTo> (AUTHOR)<i> dinghy@zjcc.org.cn</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22PLoS+ONE%22">PLoS ONE</searchLink>. 5/15/2024, Vol. 19 Issue 5, p1-12. 12p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=177250069 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1371/journal.pone.0302961 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 12 StartPage: 1 Titles: – TitleFull: Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: He, Chaoneng – PersonEntity: Name: NameFull: Mi, Xiufang – PersonEntity: Name: NameFull: Xu, Gaoqi – PersonEntity: Name: NameFull: Xu, Xinglu – PersonEntity: Name: NameFull: Xin, Wenxiu – PersonEntity: Name: NameFull: Zhong, Like – PersonEntity: Name: NameFull: Zhu, Junfeng – PersonEntity: Name: NameFull: Shu, Qi – PersonEntity: Name: NameFull: Fang, Luo – PersonEntity: Name: NameFull: Ding, Haiying IsPartOfRelationships: – BibEntity: Dates: – D: 15 M: 05 Text: 5/15/2024 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 19326203 Numbering: – Type: volume Value: 19 – Type: issue Value: 5 Titles: – TitleFull: PLoS ONE Type: main |
| ResultId | 1 |
